Drugmaker Bristol-Myers Squibb said Monday it will work with Dutch biotechnology company uniQure to develop gene therapies for cardiovascular diseases.
The companies will focus first on a treatment for congestive heart failure. They said uniQure could get more than $2.2 billion from the deal in total, and Bristol-Myers Squibb will also take a minority stake in the company.
Shares of uniQure NV climbed $10.58, or 46.3 percent, to $33.44 in midday trading. The stock went public in early 2014 and reached an all-time high of $35.50 Monday.
The companies said uniQure is studying a drug that restores the heart's ability to synthesize a protein called S100A1. Bristol-Myers Squibb could pay uniQure $254 million if that drug is successfully developed and approved for sale, and it could pay up to $217 million for each additional drug. UniQure will also get payments based on sales targets and royalties on any approved drugs. The companies will choose a total of 10 therapeutic targets.
Bristol-Myers will take a 4.9-percent stake in uniQure for about $32 million, and it will buy another 5 percent stake by the end of the year, paying a 10-percent premium for those shares. It will also get warrants that would allow it to buy another 10 percent of the company.
UniQure's only approved drug is Glybera, a genetic treatment for a rare disease called LPLD, or familial lipoprotein lipase deficiency. European Union regulators cleared the drug in 2012, and the first patients may be treated with the drug in the next few months. The drug isn't approved in the U.S.
Bristol-Myers Squibb Co. shares rose 10 cents to $63.33 in midday trading.
Explore further: FDA approves new melanoma drug from Bristol-Myers
© 2015 The Associated Press. All rights reserved.
Medical Xpress on facebook
Related Stories
Bristol-Myers to buy diabetes drug maker for $5B
(AP) — Drug maker Bristol-Myers Squibb Co. says it agreed to buy diabetes drug maker Amylin Pharmaceuticals for about $5 billion in cash.
FDA clears anticlotting drug Eliquis
The Food and Drug Administration says it has approved the anticlotting drug Eliquis, developed by Bristol-Myers Squibb Co. and Pfizer Inc. It's a potential blockbuster drug in a new category of medicines to prevent strokes ...
FDA approves new melanoma drug from Bristol-Myers
The Food and Drug Administration granted accelerated approval Monday to a new drug from Bristol-Myers Squibb to treat the deadliest form of skin cancer.
Bristol-Myers: FDA blocks hepatitis C drug for now
U.S. regulators have declined to approve Bristol-Myers Squibb's daclatasvir as part of a combination hepatitis C treatment with another antiviral drug called asunaprevir.
Bristol-Myers Squibb to buy Inhibitex for $2.5 billion
Pharmaceutical giant Bristol-Myers Squibb Company announced it was acquiring Inhibitex, Inc., a company specializing in treatment of hepatitis C, for $2.5 billion (1.9 billion euros).
Recommended for you
Review: Opioids reduce breathlessness in COPD
(HealthDay)—In chronic obstructive pulmonary disease (COPD), opioids can improve breathlessness, but not exercise capacity, according to a review published online March 24 in the Annals of the American Th ...
Patients may be modifying meds due to trouble swallowing
(HealthDay)—Some patients experience difficulties swallowing and modify medication dosage forms, without necessarily consulting health professionals, according to research published in the March issue of ...
Pfizer stops China vaccine sales as import license expires
Pfizer has stopped selling its Prevnar 7 pneumonia vaccine in China after its import license expired, but the U.S. drugmaker still intends to launch the world's most widely used vaccine, Prevnar 13, in that market.
Japan's Takeda offers $2.2 bn to settle US drug lawsuits
Japan's top drugmaker Takeda Pharmaceutical has offered $2.2 billion to settle US claims linked to its diabetes drug Actos, in what would be one of the biggest US payouts over patient lawsuits, a report said Wednesday.
Paracetamol is ineffective for lower back pain
Paracetamol is not effective in the treatment of spinal pain and provides negligible benefits for osteoarthritis, according to a study published in The BMJ today.
Why drug names are so increasingly weird
Naming a brand drug is a lot harder than it used to be.
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here to reset your password.
Sign in to get notified via email when new comments are made.
Drugmaker Bristol-Myers Squibb said Monday it will work with Dutch biotechnology company uniQure to develop gene therapies for cardiovascular diseases.
The companies will focus first on a treatment for congestive heart failure. They said uniQure could get more than $2.2 billion from the deal in total, and Bristol-Myers Squibb will also take a minority stake in the company.
Shares of uniQure NV climbed $10.58, or 46.3 percent, to $33.44 in midday trading. The stock went public in early 2014 and reached an all-time high of $35.50 Monday.
The companies said uniQure is studying a drug that restores the heart's ability to synthesize a protein called S100A1. Bristol-Myers Squibb could pay uniQure $254 million if that drug is successfully developed and approved for sale, and it could pay up to $217 million for each additional drug. UniQure will also get payments based on sales targets and royalties on any approved drugs. The companies will choose a total of 10 therapeutic targets.
Bristol-Myers will take a 4.9-percent stake in uniQure for about $32 million, and it will buy another 5 percent stake by the end of the year, paying a 10-percent premium for those shares. It will also get warrants that would allow it to buy another 10 percent of the company.
UniQure's only approved drug is Glybera, a genetic treatment for a rare disease called LPLD, or familial lipoprotein lipase deficiency. European Union regulators cleared the drug in 2012, and the first patients may be treated with the drug in the next few months. The drug isn't approved in the U.S.
Bristol-Myers Squibb Co. shares rose 10 cents to $63.33 in midday trading.
Explore further: FDA approves new melanoma drug from Bristol-Myers
© 2015 The Associated Press. All rights reserved.
Medical Xpress on facebook
Related Stories
Bristol-Myers to buy diabetes drug maker for $5B
(AP) — Drug maker Bristol-Myers Squibb Co. says it agreed to buy diabetes drug maker Amylin Pharmaceuticals for about $5 billion in cash.
FDA clears anticlotting drug Eliquis
The Food and Drug Administration says it has approved the anticlotting drug Eliquis, developed by Bristol-Myers Squibb Co. and Pfizer Inc. It's a potential blockbuster drug in a new category of medicines to prevent strokes ...
FDA approves new melanoma drug from Bristol-Myers
The Food and Drug Administration granted accelerated approval Monday to a new drug from Bristol-Myers Squibb to treat the deadliest form of skin cancer.
Bristol-Myers: FDA blocks hepatitis C drug for now
U.S. regulators have declined to approve Bristol-Myers Squibb's daclatasvir as part of a combination hepatitis C treatment with another antiviral drug called asunaprevir.
Bristol-Myers Squibb to buy Inhibitex for $2.5 billion
Pharmaceutical giant Bristol-Myers Squibb Company announced it was acquiring Inhibitex, Inc., a company specializing in treatment of hepatitis C, for $2.5 billion (1.9 billion euros).
Recommended for you
Review: Opioids reduce breathlessness in COPD
(HealthDay)—In chronic obstructive pulmonary disease (COPD), opioids can improve breathlessness, but not exercise capacity, according to a review published online March 24 in the Annals of the American Th ...
Patients may be modifying meds due to trouble swallowing
(HealthDay)—Some patients experience difficulties swallowing and modify medication dosage forms, without necessarily consulting health professionals, according to research published in the March issue of ...
Pfizer stops China vaccine sales as import license expires
Pfizer has stopped selling its Prevnar 7 pneumonia vaccine in China after its import license expired, but the U.S. drugmaker still intends to launch the world's most widely used vaccine, Prevnar 13, in that market.
Japan's Takeda offers $2.2 bn to settle US drug lawsuits
Japan's top drugmaker Takeda Pharmaceutical has offered $2.2 billion to settle US claims linked to its diabetes drug Actos, in what would be one of the biggest US payouts over patient lawsuits, a report said Wednesday.
Paracetamol is ineffective for lower back pain
Paracetamol is not effective in the treatment of spinal pain and provides negligible benefits for osteoarthritis, according to a study published in The BMJ today.
Why drug names are so increasingly weird
Naming a brand drug is a lot harder than it used to be.
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here
to reset your password.
Sign in to get notified via email when new comments are made.
0 comments:
Post a Comment